Mark Abourizk.jpg
Mark Abourizk
Former vice president, intellectual property
In August 2017 Mark Abourizk retired after 23 years at ResMed, a global designer and manufacturer of medical devices and healthcare informatics systems focused on the management of respiratory conditions and co-morbidities.

While at ResMed, Mr Abourizk was vice president of intellectual property and acted in numerous legal counsel positions.

Leading a global team of 16 IP professionals, Mr Abourizk was responsible for IP portfolio development and related transactions.

Before joining ResMed, Mr Abourizk held IP-related positions at a patent attorney firm, legal partnerships and the Commonwealth Scientific and Industrial Research Organisation.
Dianne Angus.jpg
Dianne Angus
Non executive director
Grains Research and Development Corporation
Dianne Angus has worked as an executive in the biotechnology industry for more than 20 years. She managed the joint venture alliance between Florigene (Australia) and Suntory (Japan) to yield and commercialise floricultural products and was chief operating officer of Prana Biotechnology, among other things.

Ms Angus has a passion for building competitive product portfolios – through investment in innovative research to end-stage product commercialisation. She has created global industry-academic partnerships to yield novel and competitive product candidates. Several floriculture products have realised profitable commercial sales worldwide.

Ms Angus has negotiated many commercial licences and product development agreements, with entities including large pharmaceutical and agrichemical companies and global research institutes. She has overseen the development path for novel pre-clinical agents to late-stage clinical assets before the Food and Drug Administration and European regulators.

Ms Angus has business development, regulatory, IP and finance expertise, together with strong corporate governance and compliance capabilities.
Patrick Desmond_80.jpg
Patrick Desmond
Vice president and IP counsel
USG Boral
Patrick Desmond is vice president and IP counsel at USG Boral, a building products joint venture between Boral of Australia and USG Corp in the United States. Mr Desmond is the steward for USG Boral’s intellectual property, reflected in its patents, trade secrets, trademarks, copyrights and other proprietary information.

Mr Desmond participates in USG Boral’s innovation teams, charged with stimulating, creating, capturing and protecting the enterprise’s intellectual property. Before joining USG Boral at its inception in 2014, Mr Desmond was at USG Corp for 30 years, handling IP law, licensing, global IP management, open innovation, technical transfer oversight and technology valuation. He holds two undergraduate technical degrees and an MBA. He earned his JD while working at USG, graduating as class valedictorian from the University of Toledo School of Law in Ohio. Mr Desmond is a current or former member of the state bars of Michigan, Ohio and Illinois and formerly served as the Chicago Chapter chair of the Licensing Executive Society (United States and Canada).
Christine Emmanuel (P1110308) profile picture.jpg
Christine Emmanuel
Executive manager, intellectual property and investment portfolio
Christine Emmanuel manages the IP team and IP and investment portfolios of the Commonwealth Scientific and Industrial Research Organisation (CSIRO).

She began her science career at Ciba-Geigy (United Kingdom) in 1989. Her IP career commenced at the Australian Patent Office (1992), after which she worked under UK and European law in private practice. She later joined Unilever’s patent department as in-house counsel (United Kingdom), then returned to Australia and worked for two leading patent attorney firms before moving in-house to practise intellectual property at CSIRO.

Ms Emmanuel is a registered Australian and New Zealand patent and trademark attorney and a council member of the Institute of Patent and Trademark Attorneys of Australia, where she heads the Commercialisation and Education Relations Committees.

She is passionate about managing intellectual property in order to best transition from innovation to impact, developing tools for strategic IP management, driving science direction and positioning for commercialisation.
Yen Florczak.jpg
Yen Florczak
Assistant chief IP counsel, Asia-Pacific
Since July 2016 Yen Florczak has served as assistant chief IP counsel at 3M, managing its IP team in the Asia-Pacific region and leading a team of IP professionals to support its Asia-Pacific businesses. 3M has IP offices in Bangalore, Seoul, Shanghai, Singapore, Taipei and Tokyo. Previously, Ms Florczak served as assistant chief IP counsel for 3M’s electronic and energy business group and as IP counsel to multiple 3M businesses. During her career at 3M, she has also worked as a product development engineer. Before joining the company, she worked for Abbott Laboratories in Chicago, Illinois.

Ms Florczak received her JD from the University of Minnesota Law School and is a member of the Minnesota Bar and the US Patent and Trademark Office. She received her bachelor of science degrees in chemical engineering and material science and engineering from the University of Minnesota.
Anna Gibson.jpg
Anna Gibson
Director, intellectual property
Treasury Wine Estates
Anna Gibson is director of intellectual property at Treasury Wine Estates – one of the world’s largest wine companies, listed on the Australia Securities Exchange. Ms Gibson leads the company’s global IP group and is responsible for the development and implementation of its IP policies and procedures, as well as the protection and enforcement of its wine brands – which include Penfolds, Wolf Blass, Lindemans, Matua, Wynns, Beringer and Beaulieu Vineyards – in more than 150 countries.

Before joining Treasury Wine Estates, Ms Gibson worked in the IP corporate and litigation teams of top-tier firms in Europe, New Zealand and Australia, for a range of leading brands in the fast-moving consumer goods, healthcare and fashion industries. Her formal qualifications include a bachelor of laws and a bachelor of science (hons) from the University of Auckland.
Alex Grant.jpg
Alex Grant
Alex Grant is CEO and co-founder of Myriota Pty Ltd, which offers global Internet of Things connectivity via satellite. Dr Grant was previously a professor and director of the Institute for Telecommunications Research at the University of South Australia. In 2004 he co-founded Cohda Wireless, the leading supplier of software for the connected autonomous vehicle market.

Myriota recently won the New Business category of the 2017 Telstra SA Business Awards. Dr Grant was the recipient of the 2013 Pearcey Entrepreneur Award, the 2008 Institution of Radio and Electronics Engineers Neville Thiele Award from Engineers Australia and the 2004 Young Tall Poppy Science Award. Dr Grant is an inventor on many issued patents in the intelligent transport and wireless communications fields. He has published a book and more than 150 technical papers.
Ricky Hann-2.jpg
Ricky Hann
In-house counsel
Ricky Hann is an in-house solicitor at Zespri International Limited, a kiwifruit sales and marketing company based in Mount Maunganui, New Zealand. With sales revenues of NZ$2.26 billion in 2016/17, Zespri is one of the world’s most successful horticultural marketing companies and operates an extensive kiwifruit cultivar breeding programme. The Zespri brand is recognised as a world leader in premium quality kiwifruit.

Mr Hann advises Zespri’s global marketing and innovation teams on a variety of IP-related matters involving its trademarks, designs and plant variety rights. This includes Zespri’s R&D, licensing and commercialisation arrangements. He believes that a strong IP portfolio aligned with the business strategy is critical to maintaining Zespri’s market-leading position.

Before joining Zespri, Mr Hann worked in private practice for several years. He was selected as a Young In-House Lawyer of the Year finalist at the 2017 New Zealand Law Awards.
Kathy Harrison.jpg
Kathy Harrison
Kathy Harrison is CEO of Dimerix Limited, an Australian Securities Exchange-listed drug discovery and development company with a leading programme in undergoing Phase 2 clinical trials.

Ms Harrison has more than 20 years’ experience in the Australian biotech industry, having held various roles at AMRAD, Cytopia and Phosphagenics. She also spent nine years in patent and trademark practice at Watermark, which provided a wealth of experience in the legal framework underscoring the commercialisation of technologies. Ms Harrison has led R&D functions, including product and clinical development, IP strategy and management and human resources management. She also had a lead role in a corporate merger due diligence.

Ms Harrison has a master’s of science from Manchester University, United Kingdom, and is a graduate of the Australian Institute of Company Directors. She is a registered patent and trademark attorney in Australia and a fellow of the Institute of Patent and Trademark Attorneys.
James Hutchinson.jpg
James Hutchinson
James is passionate about the important roles that science and the scientific community play in growing our economy into new high-tech and knowledge-based sectors, informing public policy and in changing our world for the better.

James has experience in supporting research & innovation in the United Kingdom and internationally with a particular focus on the life sciences and global societal challenges. He led a team of highly-knowledgeable programme specialists to develop and implement a programme of science policy, advocacy, networking, conferences, workshops and other initiatives, working in close partnership with the international chemical science community. He has a strong track record of working with government, industry and academia at senior levels.

Mr Hutchinson is a junior policy fellow of the Centre for Science and Policy at the University of Cambridge having authored more than 20 pieces of science policy, including strategic reports, government consultation responses and position statements.
Richard Johnston.jpg
Richard Johnston
IP Manager
Richard Johnston is IP manager for Gallagher Group Limited (GGL), a technology company which designs, manufactures and markets world-leading products in the areas of animal management systems, security management systems and fuel dispensing and vapour recovery systems.
The Gallagher brand has been in existence for more than 75 years and now exports from New Zealand to more than 100 countries. Mr Johnston has been managing GGL’s IP portfolio for 15 years.

Mr Johnston manages IP discovery and protection for GGL's new developments, IP maintenance, licensing and distributor agreements and the company’s trademark portfolio.

Mr Johnston is a registered lawyer and oversees the litigation and negotiation of all of GGL’s IP disputes and issues. He has been involved with a number of interesting IP cases in his time with the company.
Bob Kramer
Special counsel
Mr Kramer serves as special counsel for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP in Sydney and Washington DC. With more than 20 years of experience in intellectual property (IP) law and related antitrust, competition and standards setting issues, his practice focuses on providing meaningful protection of intellectual property rights in the US and globally. He has represented clients in numerous district courts, the US Court of Appeals for the Federal Circuit, where he also clerked, the US International Trade Commission, the Federal Trade Commission and the European Commission. Mr Kramer has particular experience in litigating complex cases concerning semiconductors, wireless and wired communications, medical devices, pharmaceuticals, gaming, sporting equipment and consumer products.

Mr Kramer regularly works with technology startups and established companies in Australia and the US to establish and improve cost-effective and timely protection of IP rights, and to integrate these rights into profitable business practices.
Brett Lunn
Managing partner
FB Rice
Brett Lunn is managing partner of FB Rice and one of Australia’s most experienced and pragmatic IP specialists. He specialises in providing strategic advice in the corporate sphere, advising a range of clients – from corporations and small and medium-sized entities to start-ups and research institutions.

Highly regarded for his ability to understand and advise on intellectual property in the context of a client’s overall business strategy, Dr Lunn brings to the advisory role a depth of understanding developed over many years working as a physicist and patent attorney.

Dr Lunn believes that patent and trademark prosecution is only one aspect of a successful IP strategy. Equally important is the role that intellectual property plays in developing a business, securing funding and building corporate assets. He sees the efficient management of intangible assets as vital to the success of any business, particularly those with a growth mandate and global aspirations.
Rebecca McCrackan.JPG
Dr Rebecca McCrackan
Senior adviser, patents and technical intellectual property
Rio Tinto
Rebecca McCrackan has more than 17 years’ experience in the life science and resource sectors and is principal adviser on patents and technical intellectual property for the global mining and metals group Rio Tinto. Her IP law experience ranges from traditional IP roles in private practice to research and innovation deployment programmes.

Ms McCrackan has a bachelor’s degree in biotechnology, a PhD in biomedicine and a master’s degree in intellectual property. She has completed the Australian Institute of Company Directors Foundations course and is a fellow of the Australian Institute of Patent and Trademark Attorneys.

Ms McCrackan specialises in intellectual asset management, IP strategy development, patent drafting and prosecution, IP adversarial matters and competitor analysis, and has a comprehensive understanding of the frameworks that underpin the successful deployment and commercialisation of innovation. Ms McCrackan manages a suite of Rio Tinto’s IP portfolio, working in partnership with the global team.
Rob McInnes
Rob McInnes is a scientist and lawyer who specialises in IP transactions. He has more than 25 years’ experience in the management, commercialisation and enforcement of IP rights.

Mr McInnes assists clients with planning, negotiating and drafting licensing and other IP agreements and setting up and financing new technology ventures.

In addition to his career as a lawyer in private practice, Mr McInnes has a degree in chemistry and has been an in-house manager of intellectual property and technology transfer with a large company.

Mr McInnes is vice president of the Licensing Executives Society International Board and has chaired its International Life Sciences and University Tech Transfer Committees. He is one of the few Australian lawyers to have met the requirements for the US-based Certified Licensing Professional qualification.
Derek Minihane
Vice president, sound processors and clinical care

Derek Minihane is head of Cochlear Ltd’s sound processors and accessories department and head of IP strategy. He is also programme manager, research and technology. Mr Minihane works within R&D and:  

  • leads a product development group responsible for the design and creation of sound processors and related hardware accessories;
  • drives Cochlear’s long-term research programme, setting its strategic direction and ensuring the delivery of research outcomes and new technologies; and
  • oversees Cochlear’s IP function and advises on all manner of IP issues.

Previously, Mr Minihane was vice president, intellectual property at Intermolecular, Inc in Silicon Valley, where he oversaw intellectual property and licensing. Before that, he was head of IP law for Altera Corporation, after gaining significant litigation, advisory and prosecution experience at various US law firms. Mr Minihane has an electrical engineering degree from Cornell University and a JD from the George Washington University National Law Centre.

Dean Moss.jpg
Dean Moss
A University of Queensland alumnus, Dean Moss has 30 years’ experience in science, academia, business, management and commercialisation in Australia, the United States and the United Kingdom.

Mr Moss has been a managing director and senior business development executive at several health and biotech companies worldwide. He also established a start-up, York Medical Technologies, in the United Kingdom. Before entering the commercial world, Mr Moss was the principal R&D scientist at Agen Biomedical. He has also worked as a National Health and Medical Research Council (NHMRC) research scientist and received the Campion-Ma-Playoust Memorial Award for Medical Research.

Mr Moss is a board member of several Australian companies and was a member of the investment committees of various pre-seed venture funds, including Uniseed, the Medical Research Commercialisation Fund and the New Zealand government’s KiwiNet. He is a member of the NHMRC Health Innovation Advisory Committee.
Andrew OBrien.jpg
Andrew O’Brien
Head, sales – Australia and New Zealand
Clarivate Analytics
Andrew O’Brien is head of sales for Australia and New Zealand at Clarivate Analytics (formerly Thomson Reuters’ IP and science business). He has 15 years’ experience in intellectual property and innovation intelligence and has recently been focusing on the development and implementation of industry-wide strategies to evaluate trends, competitive advantages and next-level innovation. Mr O’Brien is responsible for managing the Australia and New Zealand sales team and the implementation and delivery of Clarivate Analytics solutions in Australia and New Zealand, including the Derwent World Patent Index, Web of Science and Cortellis.

Mr O’Brien helps Australasia’s largest R&D-intensive companies, small and medium-sized enterprises and academic and government institutions to create maximum value from their innovations. His expertise includes identifying collaborators, big data, medical technology and existing and future state technology landscapes, as well as spearheading industry projects on behalf of government departments in the science, technology and innovation sectors.
Mark Roberts.JPG
Mark Roberts
Principal, life sciences group
Davies Collison Cave Pty Ltd
Mark Roberts has a BSc (hons) and is a registered Australian and New Zealand patent and trademark attorney. Mr Roberts is principal of the life sciences group at Davies Collison Cave Pty Ltd. He has been working with the firm’s clients since 1994 to tailor their IP strategies with commercial objectives. Mr Roberts specialises in the areas of general, organic and pharmaceutical chemistry, pharmacology, nanotechnology, food technology and medical devices. In addition to patent drafting and prosecution, he is experienced in conducting patent oppositions and advising on patent-related litigation. In 1998 Mr Roberts spent 12 months in London working in the corporate patent department of GlaxoWellcome. He is a fellow of the International Personal Training Academy of Education and a former tutor of its course on patent infringement and validity. He is also co-author of the Australian chapter of the Lexis Nexis publication International Pharmaceutical Law and Practice.
Fran Roden.jpg
Fran Roden
General manager, policy and governance group
IP Australia
Frances Roden is general manager of the policy and governance group at IP Australia. This group is responsible for the development of strategic directions and IP policy, both in Australia and abroad. The group also includes the office of the chief economist and the office of legal counsel, as well as the section in charge of IP Australia’s risk management, business continuity, ministerial support and audit functions.

Previously, Ms Roden led IP Australia’s governance secretariat team. In 2013 she was seconded to work with the Australian Public Service Commission on IP Australia’s capability review. She also spent three years working on science policy for the Department of Industry, Innovation and Science and 18 months as a departmental liaison officer.

Ms Roden has a PhD in organic chemistry (Bristol University, United Kingdom,) and is a member of the Institute of Public Administration Australian Capital Territory’s Corporate Governance Committee.
Grant Shoebridge headshot.JPG
Grant Shoebridge
Shelston IP

Grant Shoebridge is a principal at Shelston IP with over a decade of experience in pharmaceutical and biotechnology-related intellectual property.

Dr Shoebridge specialises in drafting, prosecution and opposition matters relating to molecular biology, cell biology, immunology, pharmaceuticals, medical devices and diagnostic technology. He also has expertise in securing extensions of term on pharmaceutical patents and advising on patent validity and infringement.

He is a leading Australian authority on gene-based patentable subject matter and acted for the applicant in Arrowhead Research Corporation (2016) which set an important legal precedent in relation to the patentability of gene-based pharmaceutical inventions in Australia. He has also made numerous television, radio and print media appearances as an advocate for gene patents.

Dr Shoebridge is a council member of the Institute of Patent and Trademark Attorneys of Australia, where he is the Public Relations Committee convenor.

Filippa Shub.jpg
Filippa Shub
Director, intellectual property
Filippa Shub is director of intellectual property at Starpharma, a listed Australian biotechnology company with pharmaceutical assets in various stages of development – from pre-clinical to on-market. She seeks to maximise firm value by collaboratively developing and implementing IP, commercial and research strategies. She manages the company’s IP portfolio and a range of academic and commercial partnerships and contracts.

Before joining Starpharma, Ms Shub worked with both legal firms and biotechnology companies in Australia and the United States, including Davies Collison Cave, Allens Arthur Robinson, Norwood Abbey and CSL. She has also run small companies and co-founded a Silicon Valley contract research organisation focused on supporting start-ups with their early-phase clinical studies.

Ms Shub is a registered patent and trademark attorney with qualifications in immunology and IP law from Melbourne University and an MBA from Santa Clara University.
Karen Sinclair Headshot CLR_85x85px.jpg
Karen Sinclair
Karen Sinclair is qualified in chemistry and the life sciences and has 30 years’ professional experience. She has extensive experience in intellectual asset management, including strategy development, due diligence, patent drafting, prosecution, pre-litigation practice, contentious matters and competitor analysis.

Ms Sinclair works with a diverse range of Australian start-up and small and medium-sized businesses, as well as multinationals in the chemical and pharmaceutical fields.

Formerly chair of Watermark, Ms Sinclair was a lead negotiator in the acquisition of the Watermark group by Xenith IP Limited in 2016, recognising it as an opportunity for the firm to compete more successfully in a changing marketplace. She is a senior fellow in the University of Melbourne Law Faculty.

Ms Sinclair was listed in the IAM Strategy 300 ¬in 2015 and 2016 and Asialaw Leading Lawyers in 2013. She is a member of the Licensing Executives Society International Asia-Pacific Committee.
Jari Vaario small.jpg
Jari Vaario
Head, Asia IP rights regulatory
Nokia Technologies
Jari Vaario is head of Asia IP regulatory at Nokia Technologies. He is responsible for the IP licensing of environment-related matters in Asia. Previously he was head of patent licensing for the Asia-Pacific region, and as director of IP standards was responsible for all of Nokia’s IP matters at standardisation organisations globally.

Mr Vaario previously worked for Nokia China and from 2001 to 2005 was responsible for R&D, technology, standardisation and IP rights. In China he also chaired the European Chamber of Commerce Information and Communication Technology Working Group. Before this he was involved in establishing the Nokia Research Center in Tokyo and was chief technology officer at Nokia Venture Organisation.

Mr Vaario received his MSc from Helsinki University of Technology in 1985 and PhD from the University of Tokyo in 1994. Before joining Nokia Japan in May 1998, he spent several years in academia, serving as a full professor at a national university in Japan.
Jonathan Tooth.jpg
Jonathan Tooth

Jonathan Tooth has more than 25 years’ professional experience in corporate finance and public markets, with core expertise in equity capital markets (ECM) and mergers and acquisitions (M&A). He primarily services small to mid-market companies and has particular expertise in the fast-moving consumer goods, financial services and technology sectors.

Mr Tooth has been involved in more than 20 initial public offerings, as well as ECM transactions that have collectively raised more than AU$2.5 billion and M&A transactions with a combined enterprise value exceeding AU$2 billion.

Before joining Henslow, Mr Tooth was a director and the head of corporate finance at Austock Group.
Previously, he worked in the corporate departments of two other Tier 2 brokerage firms in Melbourne and Perth, and in the corporate planning and development department of an international firm.

Mr Tooth is a non-executive director of Austock Group, Vita Life Sciences and Sensera Ltd.